| Dr Tin O Maung, MD | |
|
5999 Harpers Farm Rd, Suite W250, Columbia, MD 21044-3013 | |
| (410) 772-8822 | |
| (410) 772-9274 |
| Full Name | Dr Tin O Maung |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 25 Years |
| Location | 5999 Harpers Farm Rd, Columbia, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033117908 | NPI | - | NPPES |
| 090800200 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | D45157 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davita - Cedar Lane | Columbia, MD | Dialysis facility |
| Howard County General Hospital | Columbia, MD | Hospital |
| Mercy Medical Center Inc | Baltimore, MD | Hospital |
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-atlantic Nephrology Associates Pa | 2769469006 | 66 |
| Mid-atlantic Nephrology Associates Pa | 2769469006 | 66 |
News Archive
Colorectal cancer constitute the third most common cancer in the Western world. Their incidence constantly increases as the population ages, and despite recent advances in colorectal cancer therapy, the cancer metastasizes in every third of colorectal cancer patients, and a significant part of these patients eventually die from the disease
More than half of the patients who have suffered a stroke with no well-defined aetiology have an enlarged left atrial appendage of the heart, according to a Finnish study. The results indicate that the enlargement of the left atrial appendage may be an independent risk factor of strokes with cardiac origin.
After transgender and gender diverse minors start puberty, prescribing treatment to suppress puberty is the recommended strategy if desired and if diagnostic and treatment criteria are met. Pubertal suppression is commonly used in children who experience early puberty.
Women who take the most common fertility drugs, progesterone and clomiphene, are at a greater risk to develop thyroid cancer than those who don't, according to a study by the Institute of Cancer Epidemiology, Danish Cancer Society.
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.
› Verified 6 days ago
| Entity Name | Mid-atlantic Nephrology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356390108 PECOS PAC ID: 2769469006 Enrollment ID: O20040702001212 |
News Archive
Colorectal cancer constitute the third most common cancer in the Western world. Their incidence constantly increases as the population ages, and despite recent advances in colorectal cancer therapy, the cancer metastasizes in every third of colorectal cancer patients, and a significant part of these patients eventually die from the disease
More than half of the patients who have suffered a stroke with no well-defined aetiology have an enlarged left atrial appendage of the heart, according to a Finnish study. The results indicate that the enlargement of the left atrial appendage may be an independent risk factor of strokes with cardiac origin.
After transgender and gender diverse minors start puberty, prescribing treatment to suppress puberty is the recommended strategy if desired and if diagnostic and treatment criteria are met. Pubertal suppression is commonly used in children who experience early puberty.
Women who take the most common fertility drugs, progesterone and clomiphene, are at a greater risk to develop thyroid cancer than those who don't, according to a study by the Institute of Cancer Epidemiology, Danish Cancer Society.
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tin O Maung, MD 1589 Sulphur Spring Rd, Suite 109, Baltimore, MD 21227-2542 Ph: (410) 536-5400 | Dr Tin O Maung, MD 5999 Harpers Farm Rd, Suite W250, Columbia, MD 21044-3013 Ph: (410) 772-8822 |
News Archive
Colorectal cancer constitute the third most common cancer in the Western world. Their incidence constantly increases as the population ages, and despite recent advances in colorectal cancer therapy, the cancer metastasizes in every third of colorectal cancer patients, and a significant part of these patients eventually die from the disease
More than half of the patients who have suffered a stroke with no well-defined aetiology have an enlarged left atrial appendage of the heart, according to a Finnish study. The results indicate that the enlargement of the left atrial appendage may be an independent risk factor of strokes with cardiac origin.
After transgender and gender diverse minors start puberty, prescribing treatment to suppress puberty is the recommended strategy if desired and if diagnostic and treatment criteria are met. Pubertal suppression is commonly used in children who experience early puberty.
Women who take the most common fertility drugs, progesterone and clomiphene, are at a greater risk to develop thyroid cancer than those who don't, according to a study by the Institute of Cancer Epidemiology, Danish Cancer Society.
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.
› Verified 6 days ago
Dr. Jon Kent Minford, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 10710 Charter Dr, Suite G020, Columbia, MD 21044 Phone: 410-964-2212 Fax: 410-964-0380 | |
Dr. Jacob Cherian, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5450 Knoll North Dr, Columbia, MD 21045 Phone: 410-964-5311 Fax: 410-964-8578 | |
Dr. Tejaswi Rajasekhara Sastry, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 10710 Charter Dr, Suite G020, Columbia, MD 21044 Phone: 410-964-2212 Fax: 410-964-0380 | |
Michael Howard Kelemen, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5450 Knoll North Dr, Suite 200b, Columbia, MD 21045 Phone: 410-964-5303 | |
Dr. Jeffery Wayne Van Den Broek, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 10710 Charter Dr, Suite 110, Columbia, MD 21044 Phone: 410-992-9797 Fax: 410-730-0942 | |
Angela M. Kopack, MD Nephrology Medicare: Medicare Enrolled Practice Location: 11055 Little Patuxent Pkwy, Suite 209, Columbia, MD 21044 Phone: 410-884-1311 Fax: 410-884-6033 |